PNCA
MCID: PNC035
MIFTS: 87

Pancreatic Cancer (PNCA) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Cancer

Aliases & Descriptions for Pancreatic Cancer:

Name: Pancreatic Cancer 54 38 12 50 24 66 13 13 13 52 41 14
Pancreatic Carcinoma 12 50 24 66 52 42 14 69
Familial Pancreatic Carcinoma 50 24 56 29
Familial Pancreatic Cancer 50 24 56
Pancreatic Tumor 12 52 14
Pancreatic Carcinoma, Familial 12 69
Pancreatic Acinar Carcinoma 24 66
Pancreatic Cancer, Somatic 54 24
Pancreatic Neoplasm 12 69
Pancreas Carcinoma 50 29
Malignant Neoplasm of Body of Pancreas 12
Malignant Neoplasm of Head of Pancreas 12
Malignant Neoplasm of Tail of Pancreas 12
Hereditary Pancreatic Carcinoma 50
Malignant Neoplasm of Pancreas 69
Pancreatic Carcinoma, Somatic 54
Hereditary Pancreatic Cancer 50
Exocrine Pancreas Carcinoma 12
Cancer of the Pancreas 50
Carcinoma of Pancreas 12
Pancreatic Neoplasms 42
Ca Body of Pancreas 12
Ca Head of Pancreas 12
Ca Tail of Pancreas 12
Pancreas Neoplasm 12
Exocrine Cancer 12
Pancreas Cancer 50
Pnca 66

Characteristics:

Orphanet epidemiological data:

56
familial pancreatic carcinoma
Inheritance: Multigenic/multifactorial; Age of onset: Adult;

HPO:

32
pancreatic cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



Summaries for Pancreatic Cancer

NIH Rare Diseases : 50 familial pancreatic cancer (fpc) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). it is sometimes referred to as fpc only when there is not a known hereditary cancer syndrome in an affected family. in familial cases, pancreatic cancer often occurs before age 50 (earlier than other forms of pancreatic cancer). in 60% of cases it occurs within the head of the pancreas. symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction. pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. a specific genetic cause of fpc (in the absence of a known syndrome) has not been identified. familial cases of pancreatic cancer due to hereditary conditions may be caused by mutations in any of several genes. individuals who carry a mutation in one of these genes are often at an increased risk of other types of cancers as well. currently, only 10-20% of families with fpc will have a mutation identified by genetic testing. hereditary cancer syndromes and other inherited conditions associated with pancreatic cancer include:brca1 hereditary breast and ovarian cancer syndrome brca2 hereditary breast and ovarian cancer syndrome peutz-jeghers syndrome fammm syndrome lynch syndrome hereditary pancreatitis in many cases, inheritance of fpc is autosomal dominant; in some cases, is may be multifactorial. it is important to note that pancreatic cancer itself is not inherited, but a genetic predisposition to developing cancer is inherited. treatment may include surgical resection, chemotherapy, and/or radiotherapy. resection is the only potential cure, but most patients have advanced, non-resectable tumors by the time of diagnosis. last updated: 9/27/2016

MalaCards based summary : Pancreatic Cancer, also known as pancreatic carcinoma, is related to colorectal cancer and testicular cancer, and has symptoms including neoplasm of the pancreas, abdominal pain and constipation. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Pancreatic cancer and Signaling by GPCR. The drugs Afinitor and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and testes, and related phenotypes are Decreased viability and cellular

Disease Ontology : 12 An endocrine gland cancer located in the pancreas.

OMIM : 54 Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less... (260350) more...

MedlinePlus : 41 the pancreas is a gland behind your stomach and in front of your spine. it produces the juices that help break down food and the hormones that help control blood sugar levels. pancreatic cancer usually begins in the cells that produce the juices. some risk factors for developing pancreatic cancer include smoking long-term diabetes chronic pancreatitis certain hereditary disorders pancreatic cancer is hard to catch early. it doesn't cause symptoms right away. when you do get symptoms, they are often vague or you may not notice them. they include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. possible treatments include surgery, radiation, chemotherapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

UniProtKB/Swiss-Prot : 66 Pancreatic cancer: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Wikipedia : 71 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
id Related Disease Score Top Affiliating Genes
1 colorectal cancer 30.5 AKT1 BRCA2 CCKBR CCND1 CDKN1A CDKN2A
2 testicular cancer 30.4 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
3 interstitial lung disease 30.3 CDKN2A EGFR TP53 VEGFA
4 pancreatic cancer 4 12.2
5 pancreatic cancer/melanoma syndrome 12.2
6 pancreatic cancer 1 12.1
7 pancreatic cancer 3 12.1
8 pancreatic cancer 2 12.0
9 adenosquamous pancreas carcinoma 11.8
10 pancreatic cancer susceptibility 4 11.8
11 pancreatic cancer, childhood 11.7
12 pancreatic cancer susceptibility 1 11.7
13 pancreatic cancer susceptibility 2 11.7
14 pancreatic cancer susceptibility 3 11.7
15 dysplastic nevus syndrome 11.5
16 pancreatitis 11.2
17 von hippel-lindau syndrome 10.9
18 somatostatinoma 10.7
19 pancreatoblastoma 10.7
20 pancreas sarcoma 10.7
21 pancreatitis, hereditary 10.7
22 tropical calcific pancreatitis 10.7
23 islet cell tumor 10.7
24 brca2 hereditary breast and ovarian cancer syndrome 10.7
25 acinar cell carcinoma of pancreas 10.7
26 littoral cell angioma of the spleen 10.7
27 non-functioning pancreatic endocrine tumor 10.7
28 muscular dystrophy-dystroglycanopathy , type b, 2 10.7 AKT1 BRCA2 CCND1 CDKN1A CDKN2A EGF
29 proctitis 10.7 AKT1 CCND1 CDKN1A CDKN2A EGFR KRAS
30 nail disorder, nonsyndromic congenital, 3, 10.7 AKT1 CCND1 CDKN1A CDKN2A EGF EGFR
31 split-hand/foot malformation with long bone deficiency 1 10.7 AKT1 BRCA2 CCND1 CDKN1A EGF EGFR
32 bardet-biedl syndrome 10.7 AKT1 BRCA2 CCND1 CDKN1A CDKN2A EGF
33 pearson syndrome 10.7 AKT1 CCND1 CDKN2A EGFR KRAS MUC4
34 trachea squamous cell carcinoma 10.7 AKT1 BRCA2 CCND1 CDKN2A EGFR KRAS
35 malignant pleural solitary fibrous tumor 10.7 AKT1 CCND1 CDKN2A EGF EGFR KRAS
36 nevoid hypermelanosis, linear and whorled 10.7 BRCA2 CCND1 CDKN1A CDKN2A EGF EGFR
37 paroxysmal nocturnal hemoglobinuria 10.7 AKT1 BRCA2 CDKN2A EGFR KRAS MUC4
38 ladd syndrome 10.7 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
39 cardiomyopathy, dilated, 1h 10.7 AKT1 CCND1 CDKN1A CDKN2A MAPK1 SMAD4
40 rhinosporidiosis 10.7 AKT1 BRCA2 CDKN1A EGF EGFR KRAS
41 hypogonadotropic hypogonadism 20 with or without anosmia 10.6 CCND1 CDKN2A EGF EGFR STAT3 TP53
42 placenta praevia 10.6 CCND1 CDKN1A CDKN2A EGFR KRAS TP53
43 grade iii astrocytoma 10.6 AKT1 CCND1 CDKN2A EGF EGFR TP53
44 in situ pulmonary adenocarcinoma 10.6 AKT1 CCND1 CDKN1A CDKN2A EGFR TP53
45 glucose-6-phosphate translocase deficiency 10.6 AKT1 CDKN1A CDKN2A EGF EGFR TP53
46 adult astrocytic tumour 10.6 AKT1 CDKN1A CDKN2A EGF EGFR TP53
47 ocular melanoma 10.6 CCND1 CDKN1A CDKN2A EGF EGFR TP53
48 dental caries 10.6 AKT1 BRCA2 EGFR KRAS TP53 VEGFA
49 nasal cavity disease 10.6 AKT1 BRCA2 EGFR KRAS TP53 VEGFA
50 progesterone-receptor positive breast cancer 10.6 AKT1 BRCA2 CCND1 CDKN2A EGFR TP53

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Biliary Tract Neoplasm
Cholangitis Cholestasis
Deficiency Anemia Intestinal Obstruction
Pancreatic Agenesis 1 Pancreatitis, Hereditary
Protein-Energy Malnutrition Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to Pancreatic Cancer

Symptoms & Phenotypes for Pancreatic Cancer

Symptoms by clinical synopsis from OMIM:

260350

Clinical features from OMIM:

260350

Human phenotypes related to Pancreatic Cancer:

32
id Description HPO Frequency HPO Source Accession
1 neoplasm of the pancreas 32 HP:0002894

UMLS symptoms related to Pancreatic Cancer:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas, pruritus

GenomeRNAi Phenotypes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.54 EGFR KRAS MAPK1
2 Decreased viability GR00106-A-0 10.54 KRAS
3 Decreased viability GR00221-A-1 10.54 EGFR KRAS MAPK1 ACVR1B AKT1 CDKN2A
4 Decreased viability GR00221-A-2 10.54 KRAS ACVR1B AKT1
5 Decreased viability GR00221-A-3 10.54 CDKN2A MAPK1 AKT1
6 Decreased viability GR00221-A-4 10.54 CDKN2A EGFR MAPK1 ACVR1B AKT1
7 Decreased viability GR00231-A 10.54 MAPK1
8 Decreased viability GR00301-A 10.54 KRAS
9 Decreased viability GR00342-S-1 10.54 MAPK1
10 Decreased viability GR00342-S-2 10.54 MAPK1
11 Decreased viability GR00342-S-3 10.54 MAPK1
12 Decreased viability GR00381-A-1 10.54 KRAS
13 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.8 SST STK11 AKT1 BRCA2 CDKN1A CDKN2A
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.8 STK11 TP53 AKT1 BRCA2 CCND1 CDKN1A
15 Increased cell viability after pRB stimulation GR00230-A-1 9.26 ACVR1B AKT1 EGFR STK11

MGI Mouse Phenotypes related to Pancreatic Cancer:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 ACVR1B AKT1 BRCA2 CCND1 CDKN1A CDKN2A
2 growth/size/body region MP:0005378 10.51 ACVR1B AKT1 BRCA2 CCKBR CCND1 CDKN1A
3 digestive/alimentary MP:0005381 10.5 ACVR1B BRCA2 CCKBR CCND1 CDKN1A CDKN2A
4 endocrine/exocrine gland MP:0005379 10.49 CDKN2A EGF EGFR KRAS ACVR1B AKT1
5 immune system MP:0005387 10.48 AKT1 BRCA2 CCKBR CCND1 CDKN1A CDKN2A
6 behavior/neurological MP:0005386 10.47 AKT1 BRCA2 CCKBR CCND1 CDKN1A CDKN2A
7 embryo MP:0005380 10.47 ACVR1B AKT1 BRCA2 CDKN1A CDKN2A EGFR
8 homeostasis/metabolism MP:0005376 10.46 EGFR KRAS MAPK1 SMAD4 SST STAT3
9 integument MP:0010771 10.44 ACVR1B AKT1 BRCA2 CCKBR CCND1 CDKN1A
10 cardiovascular system MP:0005385 10.43 AKT1 CCKBR CCND1 CDKN1A CDKN2A EGFR
11 mortality/aging MP:0010768 10.42 KRAS MAPK1 PALLD RBBP8 SMAD4 SST
12 hematopoietic system MP:0005397 10.38 STAT3 STK11 TP53 VEGFA AKT1 BRCA2
13 nervous system MP:0003631 10.36 ACVR1B AKT1 BRCA2 CCKBR CCND1 CDKN1A
14 craniofacial MP:0005382 10.35 EGFR KRAS MAPK1 SMAD4 STAT3 STK11
15 neoplasm MP:0002006 10.3 RBBP8 SMAD4 STAT3 STK11 TP53 VEGFA
16 liver/biliary system MP:0005370 10.29 VEGFA AKT1 CCKBR CDKN1A CDKN2A EGFR
17 muscle MP:0005369 10.22 AKT1 CDKN1A CDKN2A EGFR KRAS MAPK1
18 normal MP:0002873 10.18 ACVR1B AKT1 BRCA2 CCND1 EGF EGFR
19 reproductive system MP:0005389 10.13 CCND1 CDKN1A CDKN2A EGF EGFR KRAS
20 limbs/digits/tail MP:0005371 10.07 BRCA2 CDKN1A EGFR KRAS SMAD4 TP53
21 no phenotypic analysis MP:0003012 10.06 ACVR1B CDKN1A CDKN2A EGFR KRAS SST
22 renal/urinary system MP:0005367 9.97 CCKBR CDKN1A EGFR KRAS SMAD4 STAT3
23 respiratory system MP:0005388 9.93 CCND1 CDKN1A CDKN2A EGFR KRAS MAPK1
24 skeleton MP:0005390 9.8 STAT3 TP53 ACVR1B AKT1 BRCA2 CCND1
25 vision/eye MP:0005391 9.36 CCND1 CDKN1A MAPK1 STAT3 STK11 TP53

Drugs & Therapeutics for Pancreatic Cancer

FDA approved drugs:

(show all 6)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis Approved March 2009
2
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
3
SecreFlo 17 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen Approved April 2002
4
Sutent 17 46 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
5
Erbitux 17 46 CETUXIMAB Imclone, Bristol-Myers Squibb Approved February 2004
6
Tarceva 17 46 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals Approved November, 2004

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 719)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
2
Iron Approved Phase 4,Phase 2 7439-89-6 23925
3
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
4
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
5
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
11
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
12
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
13
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
14
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
15
Daclizumab Approved, Investigational Phase 4,Phase 1,Phase 2 152923-56-3
16
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
17
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
18
Etanercept Approved, Investigational Phase 4,Phase 1,Phase 2 185243-69-0
19
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
20
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
22
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
23
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9041-08-1
24
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
25
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
27
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
28
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
29
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
30
Etomidate Approved Phase 4 33125-97-2 36339 667484
31
Meperidine Approved Phase 4 57-42-1 4058
32
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
33
Nicotine Approved Phase 4 54-11-5 942 89594
34
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
35
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
36
Tamoxifen Approved Phase 4 10540-29-1 2733526
37
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
38
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
39
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754 657311
40
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
41
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
42
Diphenhydramine Approved Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
43
Promethazine Approved Phase 4,Phase 2,Phase 1 60-87-7 4927
44
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
45
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
46
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
47
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
48
Desflurane Approved Phase 4 57041-67-5 42113
49
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
50
Azathioprine Approved Phase 4 446-86-6 2265

Interventional clinical trials:

(show top 50) (show all 2492)
id Name Status NCT ID Phase
1 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
2 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Unknown status NCT00920023 Phase 4
3 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
4 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
5 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4
6 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
7 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
8 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
9 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
10 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
11 A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids Unknown status NCT00693446 Phase 4
12 Peri-operative Expression Analysis of Pancreatic Stone Protein in a Surgical Study Population Unknown status NCT01258179 Phase 4
13 Prospective Random Comparing Study on EUS-guided Pseudocyst Drainage by Naso-pancreatic Tube and Stents Unknown status NCT01585662 Phase 4
14 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer Completed NCT01346410 Phase 4
15 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4
16 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4
17 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
18 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
19 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
20 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
21 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4
22 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
23 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4
24 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4
25 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4
26 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
27 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4
28 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4
29 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
30 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4
31 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection Completed NCT01914692 Phase 4
32 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
33 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4
34 A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients Completed NCT00363116 Phase 4
35 Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
36 Spy II Clinical Registry Completed NCT00751998 Phase 4
37 Long-Term Lamivudine Therapy for Chronic Hepatitis B Completed NCT00120354 Phase 4
38 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4
39 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Recruiting NCT01768988 Phase 4
40 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4
41 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4
42 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
43 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Recruiting NCT02775227 Phase 4
44 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
45 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
46 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
47 Anti-inflammatory Therapy to Improve Outcomes After TPIAT Recruiting NCT02713997 Phase 4
48 Thiopurine Induced Pancreatitis in IBD Patients Recruiting NCT02281799 Phase 4
49 The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy Recruiting NCT02127021 Phase 4
50 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pancreatic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pancreatic Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: pancreatic neoplasms

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

id Genetic test Affiliating Genes
1 Carcinoma of Pancreas 29
2 Familial Pancreatic Carcinoma 29
3 Neoplasm of the Pancreas 29
4 Familial Pancreatic Cancer 24 KRAS
5 Pancreatic Cancer 24 STK11 TP53
6 Pancreatic Cancer, Somatic 24 SMAD4 KRAS

Anatomical Context for Pancreatic Cancer

MalaCards organs/tissues related to Pancreatic Cancer:

39
Pancreas, Testes, Breast, Endothelial, Colon, Liver, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Cancer:

18
The Pancreas
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:
id Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 4326)
id Title Authors Year
1
Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism. ( 28260082 )
2017
2
The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer. ( 28347252 )
2017
3
Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy. ( 28373465 )
2017
4
Percutaneous Irreversible Electroporation for Ablation of Locally Advanced Pancreatic Cancer: Experience From a Chinese Institution. ( 28085755 )
2017
5
Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis. ( 28349057 )
2017
6
Downregulation of the N-myc downstream regulated gene 1 is related to enhanced proliferation, invasion and migration of pancreatic cancer. ( 28075464 )
2017
7
Reproductive factors, exogenous hormone use, and risk of pancreatic cancer in postmenopausal women. ( 28521283 )
2017
8
SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells. ( 28351313 )
2017
9
Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. ( 28526679 )
2017
10
Targeted Stroma in Pancreatic Cancer: Promises and Failures of Target Therapies. ( 28083912 )
2017
11
Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? ( 28516291 )
2017
12
Palmitic acid increases invasiveness of pancreatic cancer cells AsPC-1 through TLR4/ROS/NF-I_B/MMP-9 signaling pathway. ( 28088520 )
2017
13
MicroRNAa89296 targets AKT2 in pancreatic cancer and functions as a potential tumor suppressor. ( 28534950 )
2017
14
Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis. ( 28079594 )
2017
15
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. ( 28092682 )
2017
16
CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. ( 28242758 )
2017
17
Optimistic honesty: understanding surgeon and patient perspectives on hopeful communication in pancreatic cancer care. ( 28528268 )
2017
18
Failure to Treat: Audit of an Institutional Cancer Registry Database at a Large Comprehensive Cancer Center Reveals Factors Affecting the Treatment of Pancreatic Cancer. ( 28534079 )
2017
19
eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth. ( 28381547 )
2017
20
Downregulation of X-linked inhibitor of apoptosis protein by '7-Benzylidenenaltrexone maleate' sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. ( 28521307 )
2017
21
Effect of NR5A2 inhibition on pancreatic cancer stem cell (CSC) properties and epithelial-mesenchymal transition (EMT) markers. ( 27996162 )
2017
22
Isolation of circulating tumor cells in pancreatic cancer patients by immunocytochemical assay. ( 28523756 )
2017
23
Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. ( 28092686 )
2017
24
Dealing with pancreatic cancer in two different ways. ( 28527658 )
2017
25
Prognostic significance of anti-diabetic medications in pancreatic cancer: A meta-analysis. ( 28533491 )
2017
26
Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial. ( 28089484 )
2017
27
MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer. ( 28186267 )
2017
28
Nestin phosphorylation at threonines 315 and 1299 correlates with proliferation and metastasis of human pancreatic cancer. ( 28002641 )
2017
29
Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine. ( 28521448 )
2017
30
Active Systemic Treatment of Pancreatic Cancer. ( 28515255 )
2017
31
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. ( 28104621 )
2017
32
Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer. ( 28223335 )
2017
33
High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients. ( 28191612 )
2017
34
ZNF281 Promotes Growth and Invasion of Pancreatic Cancer Cells by Activating Wnt/I^-Catenin Signaling. ( 28523575 )
2017
35
Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. ( 28514751 )
2017
36
The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. ( 28534865 )
2017
37
Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey. ( 28087054 )
2017
38
Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. ( 28532457 )
2017
39
Endogenously Expressed IL-4RI+ Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo. ( 28350325 )
2017
40
Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. ( 28089829 )
2017
41
SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells. ( 28351319 )
2017
42
Downregulation of microRNA-181d had suppressive effect on pancreatic cancer development through inverse regulation of KNAIN2. ( 28381166 )
2017
43
Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). ( 28516306 )
2017
44
The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. ( 28112370 )
2017
45
ETS-1: A potential target of glycolysis for metabolic therapy by regulating glucose metabolism in pancreatic cancer. ( 27878249 )
2017
46
Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer. ( 28086830 )
2017
47
ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca(2+)/RhoA pathway. ( 28518134 )
2017
48
Improving theranostics in pancreatic cancer. ( 28513912 )
2017
49
Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. ( 28086938 )
2017
50
MiR-451 Promotes Cell Proliferation and Metastasis in Pancreatic Cancer through Targeting CAB39. ( 28197410 )
2017